$7.75
4.44%
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US59045L1061
Symbol
MRSN

Mersana Therapeutics, Inc. Stock price

$7.75
-1.34 14.76% 1M
-6.17 44.30% 6M
-28.00 78.32% YTD
-27.50 78.01% 1Y
-182.00 95.92% 3Y
-434.00 98.25% 5Y
-342.25 97.79% 10Y
-342.25 97.79% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
-0.36 4.44%
ISIN
US59045L1061
Symbol
MRSN
Industry

Key metrics

Basic
Market capitalization
$38.7m
Enterprise Value
$-20.9m
Net debt
positive
Cash
$77.0m
Shares outstanding
5.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.1 | 1.5
EV/Sales
negative | negative
EV/FCF
0.3
P/B
negative
Financial Health
Equity Ratio
-6.6%
Return on Equity
727.7%
ROCE
-285.3%
ROIC
-
Debt/Equity
-0.3
Financials (TTM | estimate)
Revenue
$34.8m | $25.6m
EBITDA
$-70.6m | $-116.3m
EBIT
$-72.0m | $-85.3m
Net Income
$-74.0m | $-67.9m
Free Cash Flow
$-79.8m
Growth (TTM | estimate)
Revenue
16.1% | -36.8%
EBITDA
35.9% | -62.2%
EBIT
35.6% | -16.3%
Net Income
29.3% | 1.9%
Free Cash Flow
40.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-203.0% | -454.5%
EBIT
-207.0%
Net
-212.9% | -265.2%
Free Cash Flow
-229.4%
More
EPS
$-14.8
FCF per Share
$-16.0
Short interest
8.8%
Employees
102
Rev per Employee
$400.0k
Show more

Is Mersana Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Mersana Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Mersana Therapeutics, Inc. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Mersana Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Mersana Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
35 35
16% 16%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
22% 22%
101%
- Research and Development Expense 72 72
19% 19%
206%
-71 -71
36% 36%
-203%
- Depreciation and Amortization 1.41 1.41
17% 17%
4%
EBIT (Operating Income) EBIT -72 -72
36% 36%
-207%
Net Profit -74 -74
29% 29%
-213%

In millions USD.

Don't miss a Thing! We will send you all news about Mersana Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mersana Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
12 days ago
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice President of Investor Relations & Corporate Communications Martin H.
Neutral
GlobeNewsWire
12 days ago
CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2025.
Neutral
GlobeNewsWire
19 days ago
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2025 on Wednesday...
More Mersana Therapeutics, Inc. News

Company Profile

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in oncology indications. Its product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC) and XMT-1536, which focuses on ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Head office United States
CEO Martin Huber
Employees 102
Founded 2001
Website www.mersana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today